5 Hidden Pharmaceutical Compliance Risks Lurking in Your Engineering Data

Global pharmaceutical manufacturing networks like yours consist of multiple sites operating in parallel. Engineering teams, maintenance teams, contractors and project teams all depend on access to technical information. Yet many organizations don't realize just how fragmented that information has become. Documentation is often spread across legacy systems, local repositories, shared drives and disconnected applications, creating document trails that span multiple locations and owners. As a result, engineering and maintenance personnel may spend significant time searching for information or unknowingly rely on inconsistent documentation when making critical decisions.

The lack of visibility and inconsistency across pharmaceutical manufacturing data creates a serious compliance risk. You likely already give significant governance attention to quality assurance systems, but what about your operational engineering documentation? Today’s operational reality is that compliance risk isn’t solely confined to quality systems anymore. Fragmented engineering documentation, inconsistent maintenance records and disconnected operational systems present real risk to the Current Good Manufacturing Practice (CGMP) requirements.

Data shows that the pharmaceutical industry paid $11.2 billion in global regulatory fines in 2024 and the average GMP fine runs $5.3 million per citation. This article highlights how fragmented data and disconnected systems lead to five hidden compliance risks global pharmaceutical manufacturing organizations face today. Keep reading for insight into what capabilities to look for in resolving these risks and how you can take control before risk turns into real exposure.

Related Read: 5 Trends Shaping the Future of Document Intelligence

Hidden Risk #1: Multiple Sources of Truth Undermines Operational Consistency

Your engineering documentation rarely stays within the same system, as local or site-specific teams often maintain their own copies, specifications and procedures. This creates the potential for multiple versions of the same document or drawing to circulate across sites.

If updates aren’t consistently distributed, your teams unknowingly work from outdated information. Where this becomes a compliance concern is in the expectation that pharmaceutical organizations be able to show document lifecycle control, traceability and consistency. The lack of version control makes it hard to prove standardized operations to regulators.

This directly challenges core GMP expectations under frameworks such as U.S. Food and Drug Administration 21 CFR Part 11 and EU GMP Annex 11, as defined by the European Medicines Agency, which require controlled document lifecycle management, version control and demonstrable traceability. Without a single source of truth, it becomes significantly harder to show document control, maintain data integrity aligned to ALCOA+ principles and prove standardized operations during inspections.

Hidden Risk #2: Disconnected Maintenance Records Weaken Traceability

To execute work safely and consistently, your maintenance teams need accurate drawings, asset documentation and maintenance histories. If that data lacks the full picture or is difficult to access, the quality of maintenance work suffers. The risk becomes even bigger when maintenance records and engineering documentation are separate.

Maintenance records do more than show work was completed; They provide traceable, regulated evidence that qualified maintenance activities were done using approved procedures. Under GMP expectations, manufacturers must be able to reconstruct what work occurred, who performed that work, what documentation was referenced and how equipment remained validated throughout its lifecycle.

If your maintenance histories, engineering drawings and change documentation remain disconnected, it’s significantly more difficult to establish evidence and validate that everything is compliant. This can weaken data integrity and complicate deviation investigations making it increasingly difficult to prove compliance in accordance with equipment maintenance and documentation expectations under 21 CFR 211.67, 21 CFR 211.182 and EU GMP chapter 3.

Hidden Risk #3: Incomplete or Inconsistent Project Handover Leads to Long-Term Documentation Gaps

With every facility expansion, equipment upgrade and modernization initiative, you generate significant volumes of engineering data. Once a project is complete, all that data must be properly transferred to the appropriate operational systems that support ongoing maintenance and compliance. However, given the number of records created, these often remain scattered across different systems and local files.

You must produce a complete, controlled record of what changed, how systems were qualified and which documentation validates the facility. If there are gaps in documentation uncertainty arises during project handover over whether equipment is maintained against approved baselines.

GMP expects manufacturers to keep complete, traceable documentation during the entire lifecycle of all facilities and equipment. Missing or inconsistent handover documentation complicates qualification reviews and delays change assessments putting pharmaceutical manufacturers at risk of noncompliance with lifecycle expectations outlined in ICH Q10, EU GMP Annex 15 and EU GMP chapter 4.

Hidden Risk #4: Site-Level Changes Can Cause Enterprise-Wide Governance Blind Spots

When engineering changes are made, it rarely affects just one of your sites. From equipment modifications to process-related updates, changes can have implications across multiple facilities, especially since your teams are likely following shared engineering standards and operating practices. GMP change control principles, including those outlined in ICH Q10 Pharmaceutical Quality System, expect manufacturers to evaluate, document and communicate these changes in a controlled and consistent manner throughout the organization.

Locally managed updates may not be reflected across your broader network, creating governance gaps and version uncertainty. This leads to inconsistent operating conditions, and any lack of centralized visibility will make it harder to prove that changes were properly controlled and communicated.

Without centralized visibility into engineering changes, you can end up with enterprise-wide governance blind spots that increase risk and audit exposure. Disconnected engineering information means you can’t show that changes were approved as well as implemented and documented.

Hidden Risk #5: Reliance on Institutional Knowledge Threatens Business Continuity

In pharmaceutical manufacturing environments, some of the most important knowledge lives in the minds of the people who operate, maintain and modify your facilities. Experienced engineers and maintenance personnel understand why certain decisions are made, which assets require attention and how historical changes shaped current approaches because they saw it all happen first hand.

At the same time, knowledge management is a formal expectation under ICH Q10. It identifies knowledge management as a fundamental element of an effective pharmaceutical quality system. All critical operational knowledge must be captured, maintained and made accessible throughout the product lifecycle. If historical insights aren’t captured in your controlled systems, you risk knowledge gaps as people retire or the organization experiences workforce transitions and employee turnover. Compliance concerns come to the forefront anytime you look to reconstruct a past decision, explain asset histories and support audit investigations.

Not capturing institutional knowledge brings risks beyond continuity as well. As part of audits and inspections, pharmaceutical manufacturers must be able to show why decisions were made, the information that supported them and how those decisions were communicated and maintained over time. A lack of complete, governed engineering records means you can’t easily reconstruct this history, increasing noncompliance exposure and risk.

Related Read: Five Multi-National Companies Thriving with Engineering Document Management Systems (EDMS)

Build a Foundation to Make Your Operations Governed and Inspection-Ready

Reducing your compliance exposure doesn’t necessarily require more documentation. What you need is better control over the engineering, maintenance and operational data you already have. Regulatory expectations are continuing to evolve, so your goal must be to create an environment where engineering, maintenance, quality and compliance teams can all work from consistent and trusted information.

You may assume your existing quality management system (QMS) or enterprise content management (ECM) platform already covers this. In reality, a QMS is primarily designed to govern quality records and compliance documentation, while a general ECM or shared drive lacks the engineering-specific revision control, asset relationships and lifecycle governance needed to manage drawings, specifications and equipment histories. Even where these platforms provide some document management capabilities, they often fall short of the purpose-built controls required for engineering documentation. That gap is where hidden risks emerge, and it’s exactly what an engineering document management system is designed to address.

That’s why operational data that is connected, governed and readily accessible, makes it easier for you to prove compliance and make decisions. To mitigate hidden compliance risks, focus on these five capabilities:

1. Connected engineering information: Reduce silos and improve visibility with a centralized system that keeps engineering drawings, specifications and technical records easily accessible.
2. Controlled, single-source documentation: Ensure consistency and decrease the risk of using outdated information by having teams work from approved, version-controlled documents that are governed throughout their lifecycle.
3. Traceable maintenance and asset history: Support compliance, investigations and decision making by leveraging a complete and connected history of maintenance activity, engineering documentation and asset records.
4. Standardized operational governance across sites: Manage engineering information consistently across your pharmaceutical manufacturing network via common processes, controls and change management best practices.
5. Inspection-ready operational data: Demonstrate compliance and respond to inspections more easily as well as uphold confidence in performance by maintaining accurate, traceable and well-governed records.

Enabling this level of information control requires an engineering document management solution that can establish this foundation, accounting for the entire document lifecycle and ensuring the right people have the right access and information at the right time.

Download: Engineering Documents Deserve More than an Enterprise Content Management System

Take Control of Your Pharmaceutical Engineering Data Governance So Risk Doesn’t Become Exposure

To demonstrate control, traceability and consistency across your manufacturing operations, it’s critical that your data be governed and accessible. Given how GMP expectations continue to evolve, compliance readiness must look at more than quality systems per department or facility. While these kinds of systems or practices may work in specific scenarios, it’s also how disconnection across your organization starts.

Strengthening the governance around your engineering information will help to reduce risk and improve audit and inspection readiness. This is the critical component to how you support standardized operations across all sites. Successful compliance and governance come from operational traceability as well as leveraging your engineering documents as operational assets and maintenance data as compliance-critical evidence.

To find out more about how Accruent can help you take control of your engineering information, read our case study with AbbVie.